Sequenta, Inc.

Developing new approaches for understanding immune system status


The LymphoSIGHT™ Platform

Our proprietary LymphoSIGHT platform for immune repertoire profiling is a simple and scalable next-generation sequencing-based laboratory process that allows each of the several million B and T cells in a sample to be characterized and quantified.


Because the immune system plays a role in many aspects of health and disease, the LymphoSIGHT platform has applications in almost all areas of medicine.


ClonoSIGHT™: MRD Detection and Quantification

The first clinical product developed using the LymphoSIGHT platform is the ClonoSIGHT process, which empowers physicians with ultra-sensitive minimal residual disease (MRD) detection and quantification for patients with lymphoid cancers.

MM Multiple Myeloma
DLBCL Diffuse Large B-Cell Lymphoma
CLL Chronic Lymphocytic Leukemia
ALL Acute Lymphoblastic Leukemia
MCL Mantle Cell Lymphoma

Clinical validation of additional indications is ongoing

Research and Development

Immune Repertoire Profiling

Sequenta conducts extensive in-house research and maintains collaborations with top academic scientists, all aimed at developing new clinical uses of the LymphoSIGHT platform. We are also working with pharmaceutical companies to incorporate our novel assay into clinical trials, where we believe immune repertoire profiling can be used to improve and accelerate drug development.



Clinical Inquiries

Sequenta, Inc.
400 East Jamie Court, Ste. 301 South San Francisco, CA 94080

T 888 552 8988
F 650 243 3897